Apellis Pharmaceuticals Inc EBIT margin

Was ist das EBIT margin von Apellis Pharmaceuticals Inc?

EBIT margin von Apellis Pharmaceuticals Inc ist -47.70%

Was ist die Definition von EBIT margin?



EBIT margin is a profitability ratio that measures earnings of the company as a percentage of revenue without taking into account the effect of taxes and interest.

ttm (trailing twelve months)

EBIT margin measures the profitability and operational efficiency of a company. It compares the amount of money that remains after the cost of goods and all operating expenses are subtracted from net revenue to sales. EBIT margin is calculated as earnings before interest and taxes divided by net revenue.

EBIT and EBIT margin evaluate how well a business manages its operations. Interest and taxes are not operating expenses and don’t impact operating efficiency. EBIT margin is usually used to compare operational efficiency and profitability of companies within the same industry. Taxes can vary by location thus excluding them from the calculation gives a better basis for comparing different companies.

EBIT and operating income are often used interchangeably, but there is a difference between them, which can cause the numbers to give different results. The key difference is that operating income does not include non-operating income, non-operating expenses, and other income.

EBIT margin von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Apellis Pharmaceuticals Inc

Was macht Apellis Pharmaceuticals Inc?

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

Unternehmen mit ebit margin ähnlich Apellis Pharmaceuticals Inc